Insider Buying: Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Buys $2,520,000.00 in Stock

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) major shareholder Foresite Capital Management V, acquired 140,000 shares of the stock in a transaction dated Monday, August 10th. The shares were acquired at an average cost of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the transaction, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Latigo Biotherapeutics Stock Performance

Shares of NASDAQ LTGO opened at $19.38 on Thursday. Latigo Biotherapeutics, Inc. has a fifty-two week low of $17.22 and a fifty-two week high of $22.47.

Latigo Biotherapeutics Company Profile

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.